基于免疫激活动力学的放疗与免疫治疗联合的放疗时机最优控制模型与仿真分析
Optimal Control Model and Simulation Analysis of Radiotherapy Timing for the Combination of Radiotherapy and Immunotherapy Based on Immune Activation Kinetics
DOI: 10.12677/aam.2026.157322, PDF,    科研立项经费支持
作者: 冯焕敏, 陈子帆:福建师范大学数学与统计学院,福建 福州
关键词: 放疗免疫治疗最优控制肿瘤体积分次间隔Radiotherapy Immunotherapy Optimal Control Tumor Volume Interfraction Interval
摘要: 放疗与免疫治疗联合应用在肿瘤控制中表现出协同效应,而放疗时机是决定疗效的关键因素。本文基于放疗与免疫治疗协同作用的肿瘤动力学模型,构建以肿瘤总体积最小化和生存时间最大化为目标的两个最优控制模型,定量分析了首次放疗时间与分次放疗间隔对治疗效果的影响。数值结果表明,尽早启动首次放疗并最大限度缩短分割间隔可显著提升联合治疗的整体疗效;此外,敏感性分析结果表明,首次放疗时间对肿瘤控制的影响显著高于分割时间间隔。
Abstract: The combined application of radiotherapy and immunotherapy shows a synergistic effect in tumor control, and the timing of radiotherapy is a key factor determining the therapeutic efficacy. Based on the tumor dynamics model of the synergistic effect of radiotherapy and immunotherapy, this paper constructs two optimal control models with the goals of minimizing the total tumor volume and maximizing the survival time. We quantitatively analyze the influence of the start time of the first fraction and the interval between fractions on the treatment effect. The numerical results show that initiating the first fraction as early as possible and minimizing the interfraction interval can significantly improve the overall efficacy of the combined treatment. Moreover, the sensitivity analysis results indicate that the impact of the start time of the first fraction on tumor control is significantly higher than that of the interfraction interval.
文章引用:冯焕敏, 陈子帆. 基于免疫激活动力学的放疗与免疫治疗联合的放疗时机最优控制模型与仿真分析[J]. 应用数学进展, 2026, 15(7): 279-290. https://doi.org/10.12677/aam.2026.157322

参考文献

[1] Force, L.M., Kocarnik, J.M., May, M.L., Bhangdia, K., Crist, A., Penberthy, L., et al. (2025) The Global, Regional, and National Burden of Cancer, 1990-2023, with Forecasts to 2050: A Systematic Analysis for the Global Burden of Disease Study 2023. The Lancet, 406, 1565-1586. [Google Scholar] [CrossRef
[2] Bhat, G.R., Hyole, R.G. and Li, J. (2021) Head and Neck Cancer: Current Challenges and Future Perspectives. Advances in Cancer Research, 152, 67-102. [Google Scholar] [CrossRef] [PubMed]
[3] Robinson, D.J., Barsoumian, H.B., Nalin, A.P., Verma, V., Niedzielski, J.S., Puebla-Osorio, N., et al. (2026) Real-World Guide for Delivering Immunotherapy with Radiation Therapy. Practical Radiation Oncology, 16, 222-233. [Google Scholar] [CrossRef
[4] Hodi, F.S., O’Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. (2010) Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 363, 711-723. [Google Scholar] [CrossRef] [PubMed]
[5] Gutiontov, S.I., Pitroda, S.P., Chmura, S.J., Arina, A. and Weichselbaum, R.R. (2020) Cytoreduction and the Optimization of Immune Checkpoint Inhibition with Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics, 108, 17-26. [Google Scholar] [CrossRef] [PubMed]
[6] 王一鸣, 于兰, 刘龑浩, 等. 局部晚期不可切除非小细胞肺癌放射免疫联合治疗研究进展[J]. 中华放射肿瘤学杂志, 2026, 35(1): 78-83.
[7] Jiang, J., Li, H., Ma, Q., Liu, J., Ren, F., Song, Y., et al. (2025) Synergies between Radiotherapy and Immunotherapy: A Systematic Review from Mechanism to Clinical Application. Frontiers in Immunology, 16, Article 1554499. [Google Scholar] [CrossRef] [PubMed]
[8] Hartley, F., Ebert, M. and Cook, A.M. (2025) Leveraging Radiotherapy to Improve Immunotherapy Outcomes: Rationale, Progress and Research Priorities. Clinical & Translational Immunology, 14, e70030. [Google Scholar] [CrossRef] [PubMed]
[9] 于金明, 滕菲菲. 放疗与免疫治疗联合应用的相关机制及研究进展[J]. 中国肿瘤临床, 2014, 41(9): 547-550.
[10] Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R.R., et al. (2014) Irradiation and Anti-PD-L1 Treatment Synergistically Promote Antitumor Immunity in Mice. Journal of Clinical Investigation, 124, 687-695. [Google Scholar] [CrossRef] [PubMed]
[11] Lynch, C., Pitroda, S.P. and Weichselbaum, R.R. (2024) Radiotherapy, Immunity, and Immune Checkpoint Inhibitors. The Lancet Oncology, 25, e352-e362. [Google Scholar] [CrossRef] [PubMed]
[12] Moore, C., Hsu, C., Chen, W., Chen, B.P.C., Han, C., Story, M., et al. (2021) Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Preclinical Models Enhances Single-Agent Immune Checkpoint Blockade. International Journal of Radiation Oncology, Biology, Physics, 110, 1306-1316. [Google Scholar] [CrossRef] [PubMed]
[13] Rouf, S., Moore, C., Saha, D., Nguyen, D., Bleile, M., Timmerman, R., et al. (2025) PULSAR Effect: Revealing Potential Synergies in Combined Radiation Therapy and Immunotherapy via Differential Equations. Journal of Theoretical Biology, 596, Article 111974. [Google Scholar] [CrossRef] [PubMed]
[14] Barendsen, G.W. (1982) Dose Fractionation, Dose Rate and Iso-Effect Relationships for Normal Tissue Responses. International Journal of Radiation Oncology, Biology, Physics, 8, 1981-1997. [Google Scholar] [CrossRef] [PubMed]
[15] 毛照昉, 王威, 方侃, 等. 基于模拟退火算法的人机协同装配线平衡问题研究[J]. 控制与决策, 2024, 39(10): 3366-3374.
[16] Li, Y.C., Kucukkoc, I. and Tang, X.W. (2021) Two-Sided Assembly Line Balancing That Considers Uncertain Task Time Attributes and Incompatible Task Sets. International Journal of Production Research, 59, 1736-1756. [Google Scholar] [CrossRef
[17] 刘雨欣, 李梓响, 郑晨昱, 等. 模型和学习驱动的模拟退火算法求解面向成本的双边装配线平衡问题[J]. 机床与液压, 2026, 54(4): 102-109.